$Novavax(NVAX)$ “Imbelieve we were late to the market, and U.S. vaccination was driven by what was available and shown to work, mRNA vaccines," said Chief Executive Officer Stanley Erck.
The dismal outlook is the latest setback for Novavax's protein-based shot, which has been plagued by manufacturing snags, regulatory delays and sluggish uptake in key markets like Europe
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments